This is a UK news story, published by Home, that relates primarily to Rinri Therapeutics news.
For more UK news, you can click here:
more UK newsFor more Rinri Therapeutics news, you can click here:
more Rinri Therapeutics newsFor more medical innovations news, you can click here:
more medical innovations newsFor more news from Home, you can click here:
more news from HomeOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like medical innovations news, you might also like this article about
auditory nerve regeneration. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest cochlear implants news, neural hearing loss news, medical innovations news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
regenerative cell therapyHome
•Health
Health
82% Informative
University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss.
Rinri Therapeutics has received approval from the UK ’s Medicines and Healthcare products Regulatory Agency (MHRA) to begin its first -in-human clinical trial.
The study aims to measure safety and detect significant changes in neural health.
VR Score
80
Informative language
82
Neutral language
7
Article tone
formal
Language
English
Language complexity
82
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
3
Source diversity
3
Affiliate links
no affiliate links